First AD

Second AD

IgAN Progression

Discuss the progressive nature of IgA nephropathy.

What are the main factors that may contribute to faster progression toward end-stage renal disease (ESRD)??

Videos

Video Series

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Advancing IgAN Care: Exploring the Next Wave of Treatments

IgA nephropathy is a chronic glomerulonephritis characterized by the deposition of IgA in the glomerular mesangium, leading to progressive renal damage. The disease course is variable, with some patients experiencing slow progression while others rapidly advance to end-stage renal disease (ESRD). Factors influencing progression include persistent proteinuria, hypertension, and reduced glomerular filtration rate (GFR) at diagnosis. Genetic predispositions and environmental factors may also play roles. Early identification and management of these risk factors are crucial in slowing disease progression and improving patient outcomes.

Panelists discuss the progressive nature of immunoglobulin AIgA nephropathy (IgAN) and identify key factors that may accelerate its progression toward end-stage renal disease (ESRD).

Overview of IgAN and Its Common Symptoms

IgAN vs Other Glomerular Diseases

Biomarkers for IgAN

Genetic Screening for IgAN

Impact of IgAN on Quality of Life

Misdiagnosis and Barriers to Early Detection of IgAN

Differential Diagnoses of IgAN

Significance of Proteinuria for Potential IgAN

Proteinuria Variability and IgAN Diagnosis

Biomarkers and Improving IgAN Diagnostic Accuracy

Primary Treatment Goals for Patients With IgAN

Proteinuria Reduction in Long-Term Kidney Damage Prevention

Symptoms Management and Targeting the Root Cause of IgAN